Navigation Links
Oxford Performance Materials Acquired By Arkema

OPM Expands Position within High Performance Polymer Market Place

Enfield, CT (PRWEB) February 9, 2009 -- Arkema has announced the acquisition of Oxford Performance Materials, Inc. (OPM), maker of OXPEKK® products. OPM will operate as an Arkema subsidiary from its Enfield, CT headquarters with the established management team. The firm will continue its commercial focus on advanced medical and industrial applications for its proprietary materials. OXPEKK® products are currently used in commercial jetliners, long-term medical implants, and demanding energy applications, including down-hole tools and pumps.

OXPEKK® polyether ketone ketone is a high-temperature and chemically resistant, semi-crystalline thermoplastic with exceptional abrasion resistance and natural flame retardancy. "The addition of OXPEKK® products to Arkema's diverse portfolio complements a set of high-performance plastics than include high-purity Kynar® Rx PVDF, biocompatible Pebax® polyether block amides, medical-grade Plexiglas® PMMA, and food-contact-compliant Biostrength® polymer additives," said Homero Endara, commercial development manager for Arkema, Inc.

"Arkema has had a long-standing interest in ultra-high-performance polymers and we have looked at strategic opportunities in the past. It was our desire to find the right combination of management committed to exploiting the medical and high-tech market space and a product that offered outstanding technical differentiation," said Ryan Dirkx, V.P. of Research and Development for Arkema, Inc. "We are delighted to have concluded this transaction and look forward to supporting OPM with the capabilities of Arkema's global organization."

"OPM has spent nearly ten years perfecting the polyethyl ketone ketone (PEKK) molecule with the help of venture capital," said Scott DeFelice, President and CEO of OPM. "Now with Arkema, we can broaden our industrial strategy and pursue more market opportunities. OPM's single-minded focus on PEKK and Arkema's polymer competencies and capabilities will be a formidable combination in the high-performance polymer marketplace."

About OPM
Founded in March 2000, OPM has rapidly become an industry leader in the ultra-high performance thermoplastic polymers market. The firm's versatile OXPEKK® polymers are currently being used in medical, space and defense, semiconductor and industrial markets worldwide. OPM is ISO 9001:2000 and ISO 13485:2003 registered. For additional information, please visit

About Arkema
A global chemical company and France's leading chemicals producer, Arkema consists of three strategically related businesses: Vinyl Products, Industrial Chemicals, and Performance Products. Arkema reported sales of 5.7 billion euros in 2007. Arkema has 15,200 employees across over 40 countries and six research centers located in France, the United States and Japan. With internationally recognized brands, Arkema holds leadership positions in its principal markets.

OXPEKK® is a registered trademark belonging to Oxford Performance Materials, Inc.
Kynar® and Biostrength® are trademarks belonging to Arkema, Inc.
Pebax® is a trademark belonging to Arkema.
Plexiglas® is a trademark belonging to Altuglas International.

# # #

Read the full story at

Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved

Related medicine news :

1. Oxford Performance Materials Received ISO 13485 and ISO 9001 Certification
2. AIDS Activists from Across the Country Converge on Oxford, Mississippi, to Call on McCain and Obama to Commit to National AIDS Strategy
3. Curemark CEO Presents Autism Findings at Prestigious Neurobiology Conference at Oxford
4. Varian, Inc. Acquires Oxford Diffraction, Ltd.
5. ESMO, Oxford Journals and the Japanese Society of Medical Oncology announce collaboration
6. Journal of American College of Surgeons study finds warm-up helps surgeons improve performance
7. Abaxis Reports Financial Performance for the Third Quarter of Fiscal 2009
8. KPMG and Trintech Collaborate to Enable Bay Area Users Group of Trintech Customers to Optimize Their Investments in Technology and Deliver Improved Performance in Turbulent Economic Times
9. AMDL, Inc. Completes Revision of Performance & Equity Incentive Compensation Plan
10. Synthetech Earns National Recognition for Performance Improvement Program
11. Park Avenue Nursing and Rehabilitation Center Selects Web-based Long-Term Care Software to Automate Admissions and Boost Census Performance
Post Your Comments:
(Date:11/27/2015)... ... November 27, 2015 , ... According to an article ... the way that they are handling security in light of the recent terrorist attacks ... in an attempt to stop an attack from reaching U.S. soil. Especially around special ...
(Date:11/27/2015)... ... November 27, 2015 , ... A team of Swiss ... to treat it. Surviving Mesothelioma has just posted the findings on the website. ... Zurich analyzed the cases of 136 mesothelioma patients who were treated with chemotherapy followed ...
(Date:11/27/2015)... ... November 27, 2015 , ... "When ... said an inventor from Hillside, N.J. "Many people catch diseases simply from sitting ... individuals will always be protected from germs." , He developed the patent-pending QUDRATECS ...
(Date:11/27/2015)... ... ... The print component of “Supporting Our Caregivers” is distributed ... Minneapolis, South Florida, with a circulation of approximately 250,000 copies and an estimated ... media strategy and across a network of top news sites and partner media ...
(Date:11/27/2015)... ... ... MPWH, the No.1 Herpes-only dating community in the world, revealed that over 50% of its ... 3.7 billion people under the age of 50 – or 67% of the population - ... estimates of HSV-1 infection . , "The data shocks us highly!" said Michelle Li, ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)... THOUSAND OAKS, Calif. , Nov. 25, 2015 /PRNewswire/ ... of a Biologics License Application (BLA) with ... Administration (FDA) for ABP 501, a biosimilar candidate to ... the first adalimumab biosimilar application submitted to the FDA ... biosimilar pathway. Sean E. Harper , M.D., ...
(Date:11/25/2015)... On Tuesday, November 24, 2015, the ... Wright Medical Technology, Inc. for product liability and ... implant device, awarded $11 million in favor of ... and three days of deliberations, the jury found ... designed and unreasonably dangerous, and that Wright Medical ...
(Date:11/25/2015)... -- Allergan plc (NYSE: AGN ) today announced that ... York State Attorney General,s Office to end the ... statutes with the Attorney General over the decision of Forest ... selling the now generic version of memantine immediate release tablets.  ... released its counterclaims against New York , ...
Breaking Medicine Technology: